The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- NVI/NVA
研究概览
简要总结
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
详细描述
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3)
- •Individuals who are ages 20-80 years old; male or female of chinese
- •Visual acuity of light perception or better in the study eye
- •Willing and able to comply with clinic visits and study-related procedures
- •Provide signed informed consent
排除标准
- •Use of intraocular anti-VEGF agents in the study eye in the past 3 months.
- •Active ocular or periocular infection in the study eye
- •Uncontrolled Blood Pressure
- •Thromboembolism
- •Congestive Heart Failure
- •Renal Failure
- •History of myocardial infarction
- •History of Stroke
- •Pregnant or breast-feeding women
- •Participation in another simultaneous medical investigator or trial
研究组 & 干预措施
Intracameral injection
Intracameral injection of conbercept for the treatment of NVG
干预措施: Intracameral injection (Procedure)
Intravitreal injection
Intravitreal injection of conbercept for the treatment of NVG
干预措施: Intravitreal injection (Procedure)
结局指标
主要结局
NVI/NVA
时间窗: 1 week and 1 month after operation
Changes in extent of iris or angle neovascularization
次要结局
- IOP(1 week and 1 month after operation)
- BCVA(1 week and 1 month after operation)